AAAF study with Sinclair Dermatology is nearing completion.
This study is a double- blind placebo controlled, prospective clinical trial comparing 1% Ruxolitinib ointment, 2% Tofacitinib ointment, 0.05% betamethasone diproprionate (an ultra-potent topical corticosteroid) ointment-to-ointment base. A total of four ointments, including a base ointment, was provided to participants in 1 gram unlabelled tubes (Tube A,B,C & D) to apply twice daily for 12 weeks. Applications were on four different areas: left and right eyebrows as well as left and right parietal scalp (above the ears).
Our preliminary results suggest promising outcomes for the use of JAK inhibitors in regrowing hair. A total of sixteen patients were successfully recruited into the trial and put on medication. 30% of patients reported spontaneous hair regrowth in both treatment areas and scalp. One patient reported complete regrowth of scalp hair and eyebrows. Regrowth is maintained 12 weeks after medication have completed. Areas treated with 2% Tofacitinib have demonstrated marginally better regrowth in comparison to 1% Ruxolitinib. In addition, 0.05% Betamethasone diproprionate (corticosteroid) have shown to result in hair regrowth in some of these patients. We are currently in the final stages of the study and in the process of analysing results. .